The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States (2017)

Peer-Reviewed Study · Ravi Gupta; Sanket S. Dhruva; Erin R. Fox; Joseph S. Ross · October 2017

Ravi Gupta et al., 2017-10: Observational study of 34 drugs addressed by the Unapproved Drugs Initiative from 2006 to 2015, finding a median 37% rise in average wholesale price and more shortages after approvals.

The UDI was associated with higher drug prices and more frequent drug shortages when compared with the period before UDI action, while the approval process for these drugs did not necessarily require new clinical evidence

p. 1066 (abstract/conclusions)

Ravi Gupta et al., 2017-10: Observational study of 34 drugs addressed by the Unapproved Drugs Initiative from 2006 to 2015, finding a median 37% rise in average wholesale price and more shortages after approvals. C2 price/availability study. Retrospective observational analysis; 34 previously unapproved prescription drugs, 26 with pricing data; median AWP change +37% (IQR 23%-204%, P<0.001); drugs in shortage 17 (50.0%) to 25 (73.5%), P=0.046; median shortage duration 31 to 217 days, P=0.053; ~90% of approvals rested on literature review or bioequivalence rather than new trials. Methylene blue is not individually named in the article, so the methylene-blue-specific price change is not established by this source. Funding: no external grants; disclosures per article. text_file=A_11.txt Study type: other.